Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.

J-Pharma, a Japan-based drug development spinout of Kyorin University, has raised ¥1.8bn ($16.3m) in a series D round involving university venturing unit Osaka University Venture Capital. Spera Pharma, a chemistry, manufacturing and controls subsidiary of drug and medical supplies producer Iwaki Group, also backed the round alongside Mizuho Capital and Mitsubishi UFJ Capital, respective VC arms…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.